Praxis Bioresearch

What Praxis Bioresearch does

Praxis Bioresearch is a privately-held, clinical-stage biopharmaceutical company founded in 2014 by Dr. Sandeep Patil and headquartered in Los Angeles, California. The company develops therapeutics for chronic neuropsychiatric conditions, with a singular focus on its lead asset PRX-P4-003 — a novel oral, gut-activated prodrug stimulant engineered to release (-)-fencamfamine (the active isomer comprising 45% of racemic fencamfamine, a DEA-listed Schedule IV substance with decades of prior clinical use) upon enzymatic cleavage by pancreatic lipase. The gut-specific activation mechanism provides structural abuse deterrence, as less than 1% of pancreatic lipase is active in the intravenous compartment, potentially qualifying the compound for Schedule IV classification in ADHD. PRX-P4-003 achieved FDA IND clearance in October 2024 for apathy in Alzheimer's Disease and is being advanced across four CNS indications: ADHD, Alzheimer's apathy, frontotemporal dementia apathy, and post-traumatic brain injury cognitive deficits.

The underlying technology is protected by composition-of-matter patents across the U.S., Europe, China, and Japan — including U.S. Patent No. 10,683,276 — expected to extend into the early 2040s with potential patent term extension. Praxis advanced the asset from discovery to IND clearance for under $7 million, materially below the industry average of approximately $30 million, using primarily non-dilutive NIH SBIR grant funding (approximately $4.4 million cumulative across NIDA in 2018 and NIA in 2021). The platform was developed entirely in-house with 100% IP ownership.

The business model is partnership-driven rather than internal commercialization. The company is pre-revenue and is actively soliciting indication-specific licensing arrangements, regional partnerships, and co-development collaborations with pharmaceutical companies, offering qualified partners access to its Virtual Data Room and IND package materials. Upon regulatory approval, PRX-P4-003 would be commercialized through standard pharmaceutical supply chains (wholesalers, specialty pharmacies, and healthcare providers) targeting addressable markets that include approximately 15.5 million US adults with ADHD and up to 70% of Alzheimer's Disease patients experiencing apathy.

Name

Praxis Bioresearch

Legal name

Praxis Bioresearch

Website

https://praxisbioresearch.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Praxis Bioresearch is a clinical-stage biopharmaceutical company developing PRX-P4-003, a gut-activated prodrug of fencamfamine's active isomer with abuse-deterrent properties, targeting ADHD, Alzheimer's apathy, FTD apathy, and post-TBI cognitive deficits.

Ownership category

akta.pro rank

Headquarters

HQ city

Sacramento

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-commercial stage; plans to commercialize PRX-P4-003 upon regulatory approval across multiple indications including ADHD, apathy in Alzheimer's Disease, FTD apathy, and post-TBI deficits.
2. Licensing and Partnership Revenue: Indication-specific licensing, regional partnerships, and broader strategic collaborations to accelerate clinical development and commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Praxis Bioresearch is developing PRX-P4-003, a novel oral gut-activated prodrug stimulant that delivers (-)-fencamfamine with built-in abuse deterrence. The lead asset is FDA IND-cleared and Phase 1 ready, positioned initially for apathy in Alzheimer's Disease with planned expansion into ADHD, apathy in Frontotemporal Dementia, and post-TBI cognitive deficits. The company is pursuing strategic partners for co-development and licensing rather than commercial sales.

Product overview

Praxis Bioresearch is a clinical-stage biopharmaceutical company with a single lead product candidate, PRX-P4-003. This novel oral prodrug stimulant is designed to deliver the active isomer of fencamfamine (a DEA-listed Schedule IV substance) with balanced dopamine/norepinephrine engagement and built-in gut-specific activation for abuse deterrence. The product is being developed across multiple CNS indications including ADHD, apathy in Alzheimer's Disease, apathy in Frontotemporal Dementia, and traumatic brain injury. The company is seeking strategic partnerships for co-development and licensing opportunities rather than operating a multi-product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• PRX-P4-003 PRX-P4-003 is a novel oral gut-activated prodrug stimulant that delivers the active (-)-isomer of fencamfamine with balanced dopamine/norepinephrine pharmacology and built-in abuse deterrence through pancreatic lipase-mediated activation in the gut. It is being developed by Praxis Bioresearch for pharmaceutical partners seeking CNS pipeline assets across ADHD, apathy in Alzheimer's Disease, apathy in Frontotemporal Dementia, and post-TBI cognitive deficits.

Quantifiable outcome

• FDA IND cleared for PRX-P4-003 in Alzheimer's Disease Apathy (October 2024)
• +3 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered board member, key advisor and advisory.

• Adam Levyboard memberStrategic or Co-development Partner · 20 September 2023Joined Board of Directors in September 2023. Brings over 25 years of experience in biopharmaceutical financial operations, business development, and strategic planning. Currently CFO/CBO at Mineralys Therapeutics. Previously CFO at Sanifit Therapeutics, CBO at Brickell Biotech and miRagen Therapeutics. Extensive investment banking background at Bank of America, Merrill Lynch, Jefferies, and Wedbush.
• Prof. Valentino Stellakey advisorStrategic or Co-development PartnerProfessor of Pharmaceutical Chemistry at University of Kansas School of Pharmacy and inventor/co-inventor of drugs including fosphenytoin (Cerebyx), Viread, Lusedra, and Captisol. Serves as Scientific Advisor and Co-inventor of PRX-P4-003. Founded Cydex Pharma, Crititech, and ProQuest Pharma.
• Dr. Jeffrey L. CummingsadvisoryStrategic or Co-development PartnerWorld-renowned Alzheimer's researcher ranked in top 0.01% of scientists and #5 in Alzheimer's disease research. Research Professor and Director at Chambers-Grundy Center for Transformative Neuroscience at UNLV. Formerly at Cleveland Clinic Lou Ruvo Center for Brain Health and UCLA. Serves on Neuroscience Advisory Group.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Tonix Pharmaceuticals: Public CNS biopharma developing therapeutics across neurology, psychiatry and immunology including stimulant-class CNS therapies and TBI-related neurological conditions. Comparable as a clinical-stage CNS developer with stimulant-adjacent pipeline.
• Corium: Public CNS specialty company commercializing Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD, a novel prodrug stimulant formulation. Directly comparable as an ADHD-focused company leveraging novel stimulant prodrug technology with abuse-deterrent properties.
• Neumora Therapeutics: Clinical-stage CNS biopharma developing novel therapeutics for neuropsychiatric disorders, including programs targeting anhedonia/apathy. Directly comparable as a private/public CNS biotech with multi-indication pipeline ambitions and novel-mechanism drug candidates.
• Supernus Pharmaceuticals: Public CNS specialty company marketing Qelbree (viloxazine ER) for ADHD, a non-stimulant and stimulant alternative. Directly comparable as a CNS specialty competitor targeting the same ADHD market with differentiated mechanisms.
• Acadia Pharmaceuticals: Public CNS biopharma with Nuplazid for Parkinson's disease psychosis and pipeline activity in dementia-related indications. Comparable as a CNS specialty company addressing underserved dementia/neuropsychiatric symptoms with novel mechanisms.
• Axsome Therapeutics: Public CNS biopharma commercializing Auvelity for depression with pipeline programs for ADHD and other CNS indications. Comparable as a CNS-focused biopharma developing novel mechanism therapies across psychiatry/neurology.
• Intra-Cellular Therapies: Public biopharma with Caplyta (lumateperone) approved for schizophrenia and depression. Comparable as a clinical-stage-to-commercial CNS company launching novel-mechanism neuropsychiatric therapies.
• Anavex Life Sciences: Public clinical-stage biopharma developing blarcamesine for Alzheimer's disease and other CNS indications. Directly comparable as a late-clinical-stage CNS biotech pursuing disease-modulating treatments in AD.
• Athira Pharma: Public clinical-stage biopharma focused on small-molecule therapeutics to restore neuronal function in neurodegenerative diseases including Alzheimer's. Comparable as a clinical-stage AD-focused CNS biotech.
• Cortexyme: Clinical-stage biopharma historically developing targeted therapeutics for Alzheimer's disease and other neurodegenerative conditions. Comparable as a clinical-stage AD biotech pursuing novel mechanism indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Praxis Bioresearch